CompletedNCT00156715
What is this study about?This study evaluated the effectiveness of Quetiapine for people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including AugustaSchizophrenia, AddictionMedication studyAges 18–65
- Countries
- United States
- Sponsor
- Dartmouth-Hitchcock Medical Center
CompletedNCT00119574
Official study titleEvaluating a Collaborative Care Model for the Treatment of Schizophrenia (EQUIP)
This study has finished and is no longer accepting participants.
In West Los AngelesSchizophreniaInterventional studyAges 18+
- Countries
- United States
- Sponsor
- US Department of Veterans Affairs
TerminatedNCT00001198
Official study titleBiochemical, Physiological, and Psychological Measures in Normal Controls and Relatives of Psychiatric Patients
This study ended early.
In BethesdaSchizophreniaObservational studyAges 6+
- Countries
- United States
- Sponsor
- National Institute of Mental Health (NIMH) (Government agency)
CompletedNCT00412373
Official study titleA Randomized, Double-blind, Placebo-controlled, Parallel- Group Study to Evaluate the Efficacy and Safety of Flexible-dose Paliperidone ER in the Treatment of Patients With Schizoaffective Disorder.
This study has finished and is no longer accepting participants.
Multiple locations, including CerritosSchizophreniaMedication studyAges 18–65
- Countries
- United States, India, Malaysia, + 3 others
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
CompletedNCT00397033
Official study titleA Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Two Dosages of Paliperidone ER in the Treatment of Patients With Schizoaffective Disorder.
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18–65
- Countries
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
CompletedNCT00407277
Official study titleNeural Inhibition as a Mechanism of Nicotine Dependence Among Persons With Schizophrenia
This study has finished and is no longer accepting participants.
In TorontoSchizophrenia, AddictionMedication studyAges 18–60
- Countries
- Canada
- Sponsor
- Centre for Addiction and Mental Health (Hospital / academic medical center)
CompletedNCT02787122
Official study titleComparison of Emotion-focused Cognitive Behavior Therapy for Patients With Schizophrenia With Standard Treatment: Effects on Psychological Parameters and Rehospitalisation
This study has finished and is no longer accepting participants.
Multiple locations, including MarburgSchizophreniaBehavioural studyAges 18–70
- Countries
- Germany
- Sponsor
- Philipps University Marburg
TerminatedNCT02949232
Official study titlePrednisolone Addition for Patients With Recent-onset Psychotic Disorder: the Role of Immune-modulating Strategies in the Treatment of Psychosis
This study ended early.
Multiple locations, including AntwerpSchizophreniaMedication studyAges 18–70
- Countries
- Belgium, Denmark, Netherlands
- Sponsor
- UMC Utrecht
CompletedNCT02160249
Official study titleRISE (Rehabilitation Intervention for People With Schizophrenia in Ethiopia): a Cluster-randomised Trial
This study has finished and is no longer accepting participants.
In Addis AbabaSchizophreniaBehavioural studyAges 18+
- Countries
- Ethiopia
- Sponsor
- London School of Hygiene and Tropical Medicine
CompletedNCT00929955
Official study titleStudy of Role of Anti-Inflammatory Agents in Patients With Schizophrenia
This study has finished and is no longer accepting participants.
In KarachiSchizophreniaMedication studyAges 18–65
- Countries
- Pakistan
- Sponsor
- Pakistan Institute of Living and Learning
CompletedNCT01999309
Official study titleSimvastatin Addition for Patients With Recent-onset Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including GroningenSchizophreniaMedication studyAges 18–50
- Countries
- Netherlands
- Sponsor
- Iris Sommer
CompletedNCT01339858
This study has finished and is no longer accepting participants.
In IndianapolisSchizophreniaMedication studyAges 16–35
- Countries
- United States
- Sponsor
- Indiana University